You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers' picks range from emerging tools like deep learning to fundamental issues like false discovery rates and infrastructure for mass spec data sharing.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
Analysts expect the South-San Francisco-based company to report $30.2 million in revenues for Q4 and $116.4 million in full-year 2019 revenues.
A survey asking researchers for their thoughts on the key developments in the field turned up applications ranging from clinical to structural.
Atreca will use Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to identify the targets of anti-cancer antibodies Atreca is developing.
Data privacy has been an issue in genomics for some time, but new regulations and improved technology could force proteomics to confront it, as well.
The additional funds follow the $25 million that the company announced in May 2019, bringing the total figure for the round to $45 million.
With new instruments and workflows able to quantify thousands of proteins in as little as five minutes, 2019 was the year proteomics cracked its throughput problem.
Researchers from France's DreamPore and their collaborators used a nanopore to distinguish between 15 of the 20 proteinogenic amino acids.
The company said that it plans to use the funds to develop and commercialize its Proteograph proteomics platform for research and clinical applications.
Researchers identified 10 protein-based tumor subtypes across five cancer types, including subtypes representing immune cell features in the tumor microenvironment.
The firm completed financing actions raising around $1.2 billion in funds that it plans to use to provide financial flexibility and fund corporate objectives.
They collected data on 59 features of more than 100,000 phosphosites and combined those features into a score predictive of a site's functional importance.
According to its developers, the software allows for the quantification several hundred proteins in five-minute DIA analyses of undepleted plasma.
The firm plans to use the proceeds to fund operation and commercial growth as well as development of its Codex and Phenoptics spatial omics platforms.
The database of proteins secreted into blood provides a resource for basic research as well as a potential list of targets for drug and diagnostics development.
With the purchase, Canopy acquires Core's CLIA facility from which it will provide its multi-omic immune profiling services.
The grants were awarded through the organization's Diagnostic Accelerator, a partnership between the charity and various philanthropic partners.
The Human Protein Atlas was founded in 2003 to map all the human proteins in cells, tissues, and organs using a variety of omics technologies.
The researchers used the SomaScan platform to measure 5,000 plasma proteins across 17,000 patients and develop protein profiles correlated to 11 health conditions.
Retraction Watch writes that a cancer researcher has had an eighth paper retracted.
Computational biologist James Taylor has died, according to Johns Hopkins University.
The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.
In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.